Rigel Pharmaceuticals | 10-Q: Quarterly report
Rigel Pharmaceuticals | 8-K: Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | ARS: Annual Report to Security Holders
Rigel Pharmaceuticals | DEFA14A: Others
Rigel Pharmaceuticals | DEF 14A: Definitive information statements
Rigel Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Rojkjaer Lisa
Rigel Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Officer Rojkjaer Lisa
Rigel Pharmaceuticals | 8-K: Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rigel Pharmaceuticals | 10-K: Annual report
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Schorno Dean L
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Santos David A
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer RODRIGUEZ RAUL R
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Furey Raymond J.
Rigel Pharmaceuticals | 8-K: Current report
Rigel Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(9.81%),Steven Boyd(9.81%)
Rigel Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.13%)
Rigel Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Morgan Stanley(8.3%),Morgan Stanley Capital Services LLC(8.1%)
Rigel Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Santos David A
No Data